Gary M. Owens Sells 21,000 Shares of Mesa Laboratories, Inc. (NASDAQ:MLAB) Stock

Mesa Laboratories, Inc. (NASDAQ:MLAB) CEO Gary M. Owens sold 21,000 shares of the stock in a transaction that occurred on Wednesday, March 19th. The stock was sold at an average price of $123.91, for a total transaction of $2,602,110.00. Following the transaction, the chief executive officer now owns 43,337 shares in the company, valued at approximately $5,369,887.67. The trade was a 32.64 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Mesa Laboratories Trading Down 2.4 %

Shares of MLAB stock opened at $125.42 on Wednesday. The stock has a 50 day simple moving average of $137.74 and a 200 day simple moving average of $129.29. Mesa Laboratories, Inc. has a 1 year low of $83.68 and a 1 year high of $155.12. The company has a current ratio of 0.71, a quick ratio of 0.53 and a debt-to-equity ratio of 0.61. The stock has a market cap of $681.53 million, a P/E ratio of -2.71 and a beta of 0.82.

Mesa Laboratories (NASDAQ:MLAB) last released its earnings results on Tuesday, February 4th. The medical instruments supplier reported $2.07 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.41 by $0.66. Mesa Laboratories had a positive return on equity of 30.23% and a negative net margin of 104.92%. On average, research analysts predict that Mesa Laboratories, Inc. will post 8 earnings per share for the current fiscal year.

Mesa Laboratories Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Monday, March 17th. Stockholders of record on Friday, February 28th were given a $0.16 dividend. This represents a $0.64 annualized dividend and a dividend yield of 0.51%. The ex-dividend date was Friday, February 28th. Mesa Laboratories’s payout ratio is presently -1.38%.

Institutional Trading of Mesa Laboratories

A number of institutional investors and hedge funds have recently made changes to their positions in MLAB. Raymond James Financial Inc. acquired a new position in Mesa Laboratories during the fourth quarter valued at approximately $32,677,000. Ameriprise Financial Inc. raised its holdings in shares of Mesa Laboratories by 191.8% during the 4th quarter. Ameriprise Financial Inc. now owns 151,862 shares of the medical instruments supplier’s stock worth $20,026,000 after buying an additional 99,819 shares in the last quarter. Conestoga Capital Advisors LLC lifted its position in shares of Mesa Laboratories by 8.3% during the 4th quarter. Conestoga Capital Advisors LLC now owns 573,037 shares of the medical instruments supplier’s stock worth $75,566,000 after buying an additional 43,927 shares during the last quarter. Jane Street Group LLC boosted its stake in Mesa Laboratories by 1,390.4% in the fourth quarter. Jane Street Group LLC now owns 34,399 shares of the medical instruments supplier’s stock valued at $4,536,000 after buying an additional 32,091 shares in the last quarter. Finally, Diamond Hill Capital Management Inc. acquired a new position in Mesa Laboratories during the fourth quarter worth about $3,512,000. Institutional investors own 90.60% of the company’s stock.

Mesa Laboratories Company Profile

Mesa Laboratories, Inc develops, designs, manufactures, sells, and services life sciences tools and quality control products and services in North America, Europe, the Asia Pacific, and internationally. The Sterilization and Disinfection Control segment offers biological, chemical, and cleaning indicators, used to assess the effectiveness of sterilization decontamination, disinfection, and cleaning processes in the pharmaceutical, medical device, and healthcare industries.